Felidale 2.5 mg Coated Tablets for Cats
Country: Netherlands
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
06-08-2012
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
thiamazole 2.5 mg
Available from:
Dechra Limited
ATC code:
QH03BB02
Pharmaceutical form:
Coated tablet
Therapeutic group:
thiamazole
Therapeutic area:
Cats
Authorization date:
2012-02-22
Summary of Product characteristics
Issued: May 2012
AN: 00442/2011
Page 1 of 6
_ _
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Felidale 2.5 mg Coated Tablets for Cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Thiamazole
2.5 mg
EXCIPIENTS:
Titanium Dioxide (E171)
1.12 mg
Erythrosine (E127)
0.01 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Coated tablet.
Pink sugar-coated biconvex tablets, 5.5 mm diameter.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy.
For the long-term treatment of feline hyperthyroidism.
4.3
CONTRAINDICATIONS
Do not use in cats suffering from systemic disease such as primary liver disease
or diabetes mellitus.
Do not use in cats showing signs of autoimmune disease.
Do not use in animals with disorders of white blood cells, such as neutropenia
and lymphopenia.
Do not use in animals with platelet disorders and coagulopathies (particularly
thrombocytopenia).
Do not use in cats with hypersensitivity to thiamazole or the excipient,
polyethylene glycol.
Issued: May 2012
AN: 00442/2011
Page 2 of 6
Do not use in pregnant or lactating females.
Please refer to section 4.7.
4.4
SPECIAL WARNINGS
As thiamazole can cause haemoconcentration, cats should always have access
to drinking water.
4.5
SPECIAL PRECAUTIONS FOR USE
Read the complete document
